Valneva provides update on recommended use of ixchiq® by elderly individuals in the united states

Saint herblain (france), may, 12 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the u.s. food and drug association (fda) and the u.s. centers for disease control and prevention (cdc), in a joint communication to the medical community, have recommended a pause in the use of valneva's single-dose live attenuated chikungunya vaccine ixchiq® in elderly individuals while ongoing investigations into reported serious adverse events (saes) are completed. this update follows an earlier recommendation from the u.s. advisory committee on immunization practices (acip) to include a precaution related to the use of ixchiq® in persons aged 65 and over and a similar decision by the european medicines agency (ema) to temporarily suspend the use of the vaccine for individuals over 65 years old pending investigation.
VALN Ratings Summary
VALN Quant Ranking